A new trading day began on Tuesday, with NewAmsterdam Pharma Company NV (NASDAQ: NAMS) stock price up 41.41% from the previous day of trading, before settling in for the closing price of $18.52. NAMS’s price has ranged from $9.39 to $26.35 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -28.76%. Meanwhile, its annual earnings per share averaged 4.36%. With a float of $42.91 million, this company’s outstanding shares have now reached $92.17 million.
Let’s determine the extent of company efficiency that accounts for 29 employees. In terms of profitability, gross margin is 99.95%, operating margin of -495.6%, and the pretax margin is -534.64%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of NewAmsterdam Pharma Company NV is 53.55%, while institutional ownership is 40.63%. The most recent insider transaction that took place on Nov 18 ’24, was worth 834,440. In this transaction 10% Owner of this company sold 33,273 shares at a rate of $25.08, taking the stock ownership to the 11,778,760 shares. Before that another transaction happened on Nov 15 ’24, when Company’s 10% Owner sold 8,530 for $25.02, making the entire transaction worth $213,436. This insider now owns 11,812,033 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.36% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Here are NewAmsterdam Pharma Company NV’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.61.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Looking closely at NewAmsterdam Pharma Company NV (NASDAQ: NAMS), its last 5-days average volume was 2.52 million, which is a jump from its year-to-date volume of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 46.56%. Additionally, its Average True Range was 1.69.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 98.48%, which indicates a significant increase from 98.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 169.96% in the past 14 days, which was higher than the 79.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.02, while its 200-day Moving Average is $19.44. However, in the short run, NewAmsterdam Pharma Company NV’s stock first resistance to watch stands at $27.62. Second resistance stands at $29.06. The third major resistance level sits at $31.75. If the price goes on to break the first support level at $23.49, it is likely to go to the next support level at $20.80. Should the price break the second support level, the third support level stands at $19.36.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
With a market capitalization of 2.42 billion, the company has a total of 92,386K Shares Outstanding. Currently, annual sales are 14,090 K while annual income is -176,940 K. The company’s previous quarter sales were 29,110 K while its latest quarter income was -16,650 K.
